Collectively these studies indicate that advanced NSCLC patients with homozygous SMARCA4 truncating mutations represent a population with a clear unmet need that likely will not benefit from the currently available targeted molecular therapy and CIT. The gene discussed is SMARCA4; the disease is non-small cell lung carcinoma.